|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OMA1 |
Gene summary for OMA1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OMA1 | Gene ID | 115209 |
| Gene name | OMA1 zinc metallopeptidase | |
| Gene Alias | 2010001O09Rik | |
| Cytomap | 1p32.2-p32.1 | |
| Gene Type | protein-coding | GO ID | GO:0001659 | UniProtAcc | Q96E52 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 115209 | OMA1 | male-WTA | Human | Thyroid | PTC | 2.60e-08 | 4.99e-02 | 0.1037 |
| 115209 | OMA1 | PTC01 | Human | Thyroid | PTC | 6.09e-09 | 1.56e-01 | 0.1899 |
| 115209 | OMA1 | PTC04 | Human | Thyroid | PTC | 1.52e-10 | 1.04e-01 | 0.1927 |
| 115209 | OMA1 | PTC05 | Human | Thyroid | PTC | 4.79e-12 | 5.29e-01 | 0.2065 |
| 115209 | OMA1 | PTC06 | Human | Thyroid | PTC | 2.50e-24 | 5.84e-01 | 0.2057 |
| 115209 | OMA1 | PTC07 | Human | Thyroid | PTC | 6.17e-22 | 4.01e-01 | 0.2044 |
| 115209 | OMA1 | ATC12 | Human | Thyroid | ATC | 4.88e-02 | -6.75e-03 | 0.34 |
| 115209 | OMA1 | ATC13 | Human | Thyroid | ATC | 2.80e-14 | 7.09e-02 | 0.34 |
| 115209 | OMA1 | ATC4 | Human | Thyroid | ATC | 4.04e-02 | -2.87e-03 | 0.34 |
| 115209 | OMA1 | ATC5 | Human | Thyroid | ATC | 7.46e-12 | 8.94e-02 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0033108111 | Thyroid | PTC | mitochondrial respiratory chain complex assembly | 65/5968 | 93/18723 | 5.60e-14 | 3.21e-12 | 65 |
| GO:000700624 | Thyroid | PTC | mitochondrial membrane organization | 68/5968 | 116/18723 | 2.47e-09 | 6.88e-08 | 68 |
| GO:0010639112 | Thyroid | PTC | negative regulation of organelle organization | 163/5968 | 348/18723 | 3.04e-09 | 8.39e-08 | 163 |
| GO:001082124 | Thyroid | PTC | regulation of mitochondrion organization | 78/5968 | 144/18723 | 2.38e-08 | 5.43e-07 | 78 |
| GO:0031667113 | Thyroid | PTC | response to nutrient levels | 201/5968 | 474/18723 | 7.00e-07 | 1.10e-05 | 201 |
| GO:005160420 | Thyroid | PTC | protein maturation | 132/5968 | 294/18723 | 1.71e-06 | 2.39e-05 | 132 |
| GO:00482846 | Thyroid | PTC | organelle fusion | 71/5968 | 141/18723 | 3.68e-06 | 4.70e-05 | 71 |
| GO:001931810 | Thyroid | PTC | hexose metabolic process | 108/5968 | 237/18723 | 6.42e-06 | 7.65e-05 | 108 |
| GO:000599614 | Thyroid | PTC | monosaccharide metabolic process | 115/5968 | 257/18723 | 9.36e-06 | 1.05e-04 | 115 |
| GO:014046714 | Thyroid | PTC | integrated stress response signaling | 17/5968 | 22/18723 | 1.58e-05 | 1.67e-04 | 17 |
| GO:00065156 | Thyroid | PTC | protein quality control for misfolded or incompletely synthesized proteins | 20/5968 | 28/18723 | 2.01e-05 | 2.04e-04 | 20 |
| GO:000600615 | Thyroid | PTC | glucose metabolic process | 90/5968 | 196/18723 | 2.54e-05 | 2.50e-04 | 90 |
| GO:00070078 | Thyroid | PTC | inner mitochondrial membrane organization | 24/5968 | 38/18723 | 7.14e-05 | 6.19e-04 | 24 |
| GO:00164859 | Thyroid | PTC | protein processing | 95/5968 | 225/18723 | 6.60e-04 | 4.15e-03 | 95 |
| GO:00349822 | Thyroid | PTC | mitochondrial protein processing | 10/5968 | 13/18723 | 1.11e-03 | 6.51e-03 | 10 |
| GO:001082318 | Thyroid | PTC | negative regulation of mitochondrion organization | 25/5968 | 49/18723 | 4.09e-03 | 1.95e-02 | 25 |
| GO:010610613 | Thyroid | PTC | cold-induced thermogenesis | 61/5968 | 144/18723 | 5.08e-03 | 2.35e-02 | 61 |
| GO:012016113 | Thyroid | PTC | regulation of cold-induced thermogenesis | 61/5968 | 144/18723 | 5.08e-03 | 2.35e-02 | 61 |
| GO:00080534 | Thyroid | PTC | mitochondrial fusion | 15/5968 | 27/18723 | 9.19e-03 | 3.79e-02 | 15 |
| GO:199084513 | Thyroid | PTC | adaptive thermogenesis | 64/5968 | 157/18723 | 1.14e-02 | 4.50e-02 | 64 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OMA1 | SNV | Missense_Mutation | c.304N>A | p.Asp102Asn | p.D102N | Q96E52 | protein_coding | tolerated_low_confidence(0.41) | benign(0) | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| OMA1 | SNV | Missense_Mutation | rs768227326 | c.1503N>A | p.Met501Ile | p.M501I | Q96E52 | protein_coding | tolerated(0.19) | benign(0.011) | TCGA-A7-A26J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| OMA1 | SNV | Missense_Mutation | c.244N>G | p.Leu82Val | p.L82V | Q96E52 | protein_coding | tolerated_low_confidence(0.07) | benign(0.03) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| OMA1 | SNV | Missense_Mutation | rs369792266 | c.53G>A | p.Arg18Gln | p.R18Q | Q96E52 | protein_coding | tolerated_low_confidence(0.28) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| OMA1 | SNV | Missense_Mutation | c.982G>A | p.Glu328Lys | p.E328K | Q96E52 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E9-A1ND-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD | |
| OMA1 | insertion | In_Frame_Ins | novel | c.971_972insGGGCAA | p.Leu324_Leu325insGlyAsn | p.L324_L325insGN | Q96E52 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| OMA1 | SNV | Missense_Mutation | c.1381G>A | p.Glu461Lys | p.E461K | Q96E52 | protein_coding | tolerated(0.07) | benign(0.001) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| OMA1 | SNV | Missense_Mutation | novel | c.1462N>C | p.Ser488Pro | p.S488P | Q96E52 | protein_coding | deleterious(0.03) | benign(0.143) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| OMA1 | SNV | Missense_Mutation | rs181552885 | c.106N>T | p.Arg36Trp | p.R36W | Q96E52 | protein_coding | deleterious_low_confidence(0.02) | benign(0.109) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| OMA1 | SNV | Missense_Mutation | c.1491G>T | p.Lys497Asn | p.K497N | Q96E52 | protein_coding | deleterious(0.05) | benign(0.077) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |